12th AGAH Annual Meeting 2003
Annual Meeting 2003, Bonn
Back to the Future – Upgrading classical test strategies for innovative drugs
February 23 – 25, 2003, Bonn, Germany
Workshops and sessions during the pre-symposium day concentrated on medical and report writing, the FDA guidelines referring to time-series data, the Declaration of Helsinki and the European directives regulating the conduct of clinical trials. Symposium and Poster sessions focussed on current regulatory and socio-economical aspects of drug development and their perspectives, the evolution of clinical trial methods, especially in the development of anti-cancer, anti-inflammatory, anti-neurodegenerative and genetically engineered drugs.
Session I: Today's Setting of Drug Development
R. Shah, London
Risk-benefit Evaluation in Approval of traditional and innovative Drugs (Abstract)
No presentation available
M. Holz-Slomczyk, BfArM, Bonn
Guidelines for Drug Approval – Today and Tomorrow (Abstract)
No presentation available
Session II: Socioeconomic acpects of new Drugs
Workshop on the German Medicinal Act (AMG) – Presentations
M. Schlander, Witten-Herdecke
What-does-the-society-want-Schlander_01
What does the society want?
J. Göben, BfArM, Bonn
What can the Society afford? (Abstract)
No presentation available
Session III: Essential Tools – Today and Tomorrow
B. Meibohm, Memphis
Exposure/Response vs. Dose/Response Relationship in Drug Development (Abstract)
No presentation available
E. Wingender, Göttingen
Using Bioinformatics for bridging the Genotype-Phenotype Gap (Abstract)
No presentation available
Session IV: Development of Anticancer Drugs
B. Osterwalder, Basel
Xeloda, an old cytotoxic in a new Form: new Development Paradigm required? (Abstract)
No presentation available
D. Voliotis, Wuppertal
Safety, Toxicity and Efficacy of Antineoplastic Compounds – a clinical View (Abstract)
No presentation available
D. Laurent, Berlin
Design and Evaluation of clinical Studies with Angiogenesis Inhibitors (Abstract)
No presentation available
Session V: Development of Anti-inflammatory Drugs
K. Brune, Erlangen-Nürnberg
Methods to assess the Safety and Efficacy of traditional Compounds (NSAID, Steroids) [Abstract]
No presentation available
M. F. Neurath, Mainz
Inflammatory Bowel Disease: Cytokines and Cytokine Therapies (Abstract)
No presentation available
Session VI: Development of Anti-Neurodegenerative Drugs
C. Gilles, Rouffach, France
Functional MRI in neurodegenerative Disease (Abstract)
No presentation available
A. Lammertsma, Amsterdam
Potential use of PET in Drug Development: labelled Drugs, functional Changes (e.g. Flow and Metabolism), Receptor Occupancy, Dose Response Curves (Abstract)
No presentation available
Session VII: Development of genetically engineered Drugs
U. Keilholz, Berlin
Gene- and Immunotherapy in Oncology: Study Concepts, Endpoints and first Results (Abstract)
No presentation available
V. Kessler, Freiburg
Tissue Engineering (Abstract)
No presentation available
F. Jakob, Würzburg
Stem Cell Therapy (Abstract)
No presentation available
Workshops
R. Hermann, Frankfurt, W. Haverkamp, Berlin, U. Bischoff, Hamburg
QTc – „Time series data“ (Abstract)
No presentation available
K. Breithaupt-Grögler, Frankfurt and B. Hughes-Formella, Hamburg
Medical Writing – Report Writing (Abstract)
No presentation available
T. Sudhop, Bonn
K. Olejniczak, BfArM, Bonn
Preclinical requirements to studies in children (Abstract)
No presentation available
23. February 2003 - 25. February 2003
12th AGAH Annual Meeting 2003
Annual Meeting 2003
Bonn
Deutschland